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Abstract
Background: Muscle quantity at intensive care unit (ICU) admission has been independently associated with
mortality. In addition to quantity, muscle quality may be important for survival. Muscle quality is influenced by fatty
infiltration or myosteatosis, which can be assessed on computed tomography (CT) scans by analysing skeletal
muscle density (SMD) and the amount of intermuscular adipose tissue (IMAT). We investigated whether CT-derived
low skeletal muscle quality at ICU admission is independently associated with 6-month mortality and other
clinical outcomes.
Methods: This retrospective study included 491 mechanically ventilated critically ill adult patients with a CT scan of
the abdomen made 1 day before to 4 days after ICU admission. Cox regression analysis was used to determine the
association between SMD or IMAT and 6-month mortality, with adjustments for Acute Physiological, Age, and
Chronic Health Evaluation (APACHE) II score, body mass index (BMI), and skeletal muscle area. Logistic and linear
regression analyses were used for other clinical outcomes.
Results: Mean APACHE II score was 24 ± 8 and 6-month mortality was 35.6%. Non-survivors had a lower SMD
(25.1 vs. 31.4 Hounsfield Units (HU); p < 0.001), and more IMAT (17.1 vs. 13.3 cm2; p = 0.004). Higher SMD was associated
with a lower 6-month mortality (hazard ratio (HR) per 10 HU, 0.640; 95% confidence interval (CI), 0.552–0.742; p < 0.001),
and also after correction for APACHE II score, BMI, and skeletal muscle area (HR, 0.774; 95% CI, 0.643–0.931; p = 0.006).
Higher IMAT was not significantly associated with higher 6-month mortality after adjustment for confounders. A 10 HU
increase in SMD was associated with a 14% shorter hospital length of stay.
Conclusions: Low skeletal muscle quality at ICU admission, as assessed by CT-derived skeletal muscle density, is
independently associated with higher 6-month mortality in mechanically ventilated patients. Thus, muscle quality as
well as muscle quantity are prognostic factors in the ICU.
Trial registration: Retrospectively registered (initial release on 06/23/2016) at ClinicalTrials.gov: NCT02817646.
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Background
Muscle wasting is a severe complication of critical illness
[1]. Puthucheary et al. reported a steady decrease in skel-
etal muscle mass of almost 20% during the first 10 days of
intensive care unit (ICU) admission [2]. Loss of muscle
has been associated with longer duration of mechanical
ventilation and higher ICU and hospital mortality [3–5]. If
patients survive, they exhibit long-term functional disabil-
ity with a great impact on quality of life for as long as 5 to
8 years after admission [6–8]. However, many patients
already have a low muscle quantity upon admission to the
ICU. In two retrospective studies as much as 60–70% of
patients had low muscle quantity as assessed on computed
tomography (CT) scans on ICU admission, and low
muscle quantity at ICU admission was associated with a
higher mortality [9, 10].
Not only the quantity, but also the quality of muscle
seems important [11]. Along with a decline in muscle
mass, fatty infiltration of muscles or myosteatosis has
been identified as a possible cause of loss of muscle
quality [11]. Myosteatosis can be apparent within muscle
fibres and evaluated on CT scans by measuring skeletal
muscle density (SMD), or between muscle fibres and
evaluated on CT scans by measuring the amount of adi-
pose tissue between muscles (also termed intermuscular
adipose tissue or IMAT). A lower SMD was associated
with increased lipid infiltration in muscle biopsies and
poor clinical outcomes in non-ICU populations [12–14].
Additionally, a recent study in critically ill patients using
ultrasound of the quadriceps muscle found that not only
a decrease in muscle quantity but also increased muscle
echogenicity was related to a decrease in muscle func-
tion [15]. An increased amount of IMAT as assessed on
CT scans has been associated with decreased muscle
function and increased (systemic) inflammation in non-
ICU populations [16, 17]. The aim of the present study
was to investigate if muscle quality, as assessed by CT-
derived SMD and IMAT, is associated with mortality in-
dependently of muscle quantity and severity of illness.
We hypothesized that low SMD and high IMAT at ICU
admission are associated with a poor outcome, inde-
pendent of the quantity of muscle and severity of illness.
Methods
Patients and data
This is a retrospective analysis of CT-derived muscle
quality at a single time point at ICU admission in critic-
ally ill patients admitted to a mixed medical-surgical
ICU of a university hospital from September 2003 to
April 2013. Patients were included if they were aged
18 years or older, stayed in the ICU for at least 4 days,
required mechanical ventilation during their ICU stay,
and had an abdominal CT scan made 1 day before or up
to 4 days after admission to the ICU. Patients were
excluded if the CT scan was not eligible for analysis, or if
data on body weight or height or the Acute Physiological,
Age, and Chronic Health Evaluation (APACHE) II
score was missing. By searching the hospital infor-
mation system for any patients meeting inclusion cri-
teria, we expanded our previously reported cohort of
ICU patients [9].
Patient data including age, sex, weight, height, admis-
sion diagnosis, APACHE II score, length of ventilation
(LOV), ICU length of stay (ICU-LOS) and hospital length
of stay (hospital-LOS), discharge destination, and ICU and
hospital mortality was obtained from the ICU patient data
management system (Metavision; IMDsoft, Tel-Aviv,
Israel) and the hospital information system (Mirador;
iSOFT Nederland BV, Leiden, The Netherlands). If mor-
tality data were not registered, these were collected from
the civil registry or from the general practitioner.
CT scan analysis
The precision of single slice CT scan analysis at the third
lumbar vertebra (L3) level is high (inter- and intra-
observer variability less than 2% in healthy volunteers)
[18]. Both skeletal muscle area (r = 0.83–0.99; p < 0.01)
and IMAT (r = 0.39–0.61; p < 0.05) at this level are
closely related to whole body skeletal muscle and IMAT
volumes as assessed by magnetic resonance imaging
(MRI) [19–21].
CT scans made 1 day before to 4 days after ICU admis-
sion for diagnostic purposes were imported from the hos-
pital radiology system and stored on a secure computer
system. Scans were analysed using Slice-O-matic versions
4.3 and 5.0 (TomoVision, Montreal, QC, Canada) by two
trained and certified investigators (WGPML and IMD,
trained by the Cross Cancer Institute, Edmonton, AB,
Canada) who had frequent consultation with each other if
there was any doubt about eligibility, landmarking, or
analysis.
The CT scans were analysed for eligibility and rejected
if the scan quality was too low for analysis or if they
contained artefacts, or if muscle was cut off due to win-
dowing. Landmarking was performed by identifying the
L3 and isolating the CT slice that depicted the whole
vertebra the best. A bony landmark was used to ensure
reproducibility and consistency between patients.
Different tissues were identified using boundaries in
Hounsfield Units (HU) set to –29 to +150 for muscle, –190
to –30 for IMAT and subcutaneous adipose tissue,
and –150 to –50 for visceral adipose tissue [22]. SMD
was assessed by the mean radiological muscle attenuation
of all muscle visible at the L3 level, measured in HU. The
HU scale is a radiological scale describing the density of
tissues on CT scans [23]. Lower mean muscle attenuation
indicates less dense muscle tissue with more lipid infiltra-
tion, e.g. lower SMD, while a higher mean muscle
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attenuation indicates denser muscle tissue with less lipid
infiltration, e.g. higher SMD [14]. IMAT was assessed by
identifying all visible adipose tissue within muscle fascia in
cm2 [22]. Previously found ICU-specific optimal cut-off
points related to hospital mortality were used to define
low skeletal muscle area: below 170 cm2 for male patients
and below 110 cm2 for female patients [9]. See Fig. 1 for
an example of CT scan analysis.
Because muscle quality is important for dealing with
recovery after ICU and hospital discharge, we chose
6-month mortality as the primary endpoint. Secondary
endpoints were the odds of being discharged from the
hospital to home, length of ventilation, and ICU and hos-
pital LOS in survivors.
Statistics
Independent sample t tests were used to compare
survivors and non-survivors for normally distributed
continuous variables, and Mann-Whitney U tests for
non-normally distributed continuous variables. Fisher
exact and Chi2 tests with post-hoc Bonferroni analysis
were used to compare survivors and non-survivors for
categorical variables. Kaplan-Meier plots were made to
visualize the effect of SMD and IMAT (divided into two
groups based on the median) on 6-month mortality, with
log-rank tests to compare the survival curves of the two
groups. Cox regression analysis was used to evaluate the
association between SMD or IMAT (as continuous vari-
ables) and 6-month mortality. After univariable analyses,
APACHE II score was added to the models to adjust for
severity of illness (model 2). In the second adjusted
model, body mass index (BMI), and skeletal muscle area
were included as well (model 3). Age is included in the
APACHE II score and was therefore not separately
included in the adjusted models. Additionally, we
performed analyses on the subgroup of patients with
available data on visceral and subcutaneous adipose tis-
sue in which BMI was substituted with visceral and sub-
cutaneous adipose tissue as a measure of total body
fatness (model 4).
Logistic and linear regression analyses were used to
evaluate the association between SMD or IMAT and the
secondary outcome measures discharge to home, LOV,
ICU-LOS, and hospital-LOS in survivors. LOV, ICU-
LOS, and hospital-LOS were non-normally distributed
and positively skewed; therefore, the analysis was per-
formed on the natural logarithm of the variables. By re-
transforming by using the inverse, the influence of a
given predictor was calculated as a percentage change in
outcome.
Fig. 1 Example of CT scan analysis. This image shows CT scans at the level of lumbar vertebra 3 of two patients both un-analysed (upper row)
and analysed (lower row). The analysed images show muscle tissue (red) and intermuscular adipose tissue (IMAT, green). The patient on the left
has more muscle (165 vs. 120 cm2), less IMAT (10 vs. 19.5 cm2), and higher mean skeletal muscle density (42 vs. 18 Hounsfield Units) than the
patient on the right
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IBM SPSS Statistics 22 (IBM Corp, Armonk, NY,
USA) was used for statistical analysis. Values are re-
ported as mean ± standard deviation (SD) or median and
25–75% interquartile range (IQR). All statistical tests
were two-sided. A p < 0.05 was considered statistically
significant.
Results
A total of 13,434 patients were admitted to the ICU
during the study period with a mean APACHE II
score of 17.4 ± 9.2. Six hundred and seventy-eight pa-
tients fulfilled inclusion criteria and had their CT
scans imported from the radiology system to be ana-
lysed for eligibility. CT scans that were found not to
be eligible were due to artefacts (78 scans), muscle
cut-off (50 scans), or low quality (47 scans). Finally,
491 patients (72%) with complete clinical data and
good quality CT scans were included for the statistical
analysis. However, due to windowing or artefacts, vis-
ceral and/or subcutaneous adipose tissue could not be
analysed in 154 patients. We therefore performed
subgroup analyses that included visceral and subcuta-
neous adipose tissue in a subgroup of 337 patients
(50%). Figure 2 is the consort diagram showing the
inclusion process.
Patient characteristics
Patient characteristics are presented in Table 1 for 6-month
survivors and non-survivors. Outcome measures are pre-
sented separately in Table 2. CT scans were mostly made on
the day of admission to the ICU. Three hundred and twelve
(64.7%) patients had a low skeletal muscle area at ICU ad-
mission. Six-month mortality was 35.6%. Non-survivors were
older (67 ± 14 vs. 55 ± 18 years; p < 0.001), had a lower BMI
(24.6 ± 4.3 vs. 25.5 ± 4.4 kg/m2; p= 0.042), higher APACHE
II score (27 ± 8 vs. 22 ± 8; p < 0.001), and were more often
medical patients (62% vs. 43%; p < 0.001) than survivors.
Mean SMD at ICU admission was 29.9 ± 11.7 HU. Me-
dian IMAT at ICU admission was 13.6 (8.4–24.3) cm2,
comprising 9.1% of total tissue within muscle fascia
(skeletal muscle area plus IMAT) at the L3 level. Non-
survivors had a lower skeletal muscle area (120.3 ± 33.0 vs.
143.5 ± 38.9 cm2; p < 0.001), lower SMD (25.1 ± 9.4 vs.
31.4 ± 11.7 HU; p < 0.001), and more IMAT (17.1 (10.5–
27.1) vs. 13.3 (7.9–23.2) cm2; p = 0.004) than survivors.
Association between muscle quality and 6-month
mortality
Mortality was significantly higher in patients with low
muscle quality with SMD values below the median or
IMAT values above the median (Fig. 3).
Fig. 2 Consort diagram showing the inclusion process. CT computed tomography, ICU intensive care unit
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Cox regression analysis showed that higher SMD was
associated with lower 6-month mortality (hazard ratio
(HR) per 10 HU, 0.640; 95% confidence interval (CI),
0.552–0.742; p < 0.001; Table 3). This association was
still apparent when SMD was adjusted for the confounders
APACHE II score, BMI, and skeletal muscle area (HR per
10 HU, 0.774; 95% CI, 0.643–0.931; p = 0.006).
Cox regression analysis showed that higher IMAT was
associated with higher 6-month mortality (HR per 10 cm2,
1.153; 95% CI, 1.042–1.277; p = 0.006). However, when







P value survivors vs.
non-survivors
Mean/median/n SD/IQR/% Mean/median/n SD/IQR/% Mean/median/n SD/IQR/%
Age, years 58 ±18 55 ±18 67 ±14 <0.001
Sex, male, n (%) 305 62% 191 64% 93 56% 0.135
BMI, kg/m2 25.2 ±4.3 25.5 ±4.4 24.6 ±4.3 0.042
Underweight2, n (%) 19 4.1% 11 3.7% 8 4.8% 0.291
Normal weight2, n (%) 238 51.3% 145 48.5% 93 56.4%
Overweight2, n (%) 158 34.1% 108 36.1% 50 30.3%
Obesity2, n (%) 49 10.6% 35 11.7% 14 8.5%
APACHE II score 24 ±8 22 ±8 27 ±8 <0.001
Admission category, n (%) 0.001
Medical 248 50.5% 130 43% 102 62%
Surgical 243 49.5% 169 57% 63 38%
Admission diagnosis, n (%) <0.001
Cardiovascular 32 6.5% 18a 6.0% 14a 8.5%
Metabolic/renal 15 3.1% 8a 2.7% 6a 3.6%
Neurologic 41 8.4% 19a 6.4% 16a 9.7%
Post-resuscitation 28 5.7% 16a 5.4% 11a 6.7%
Post-surgery 149 30.3% 95a 31.8% 50a 30.3%
Respiratory insufficiency 68 13.8% 40a 13.4% 25a 15.2%
Sepsis 31 6.3% 14a 4.7% 15a 9.1%
Trauma 94 19.1% 74a 24.7% 13b 7.9%
Other 33 6.7% 15a 5.0% 15a 9.1%
Length of hospital stay before
ICU admission, days
0 0–4 0 0–4 0 0–6 0.166
Time from ICU admission to
CT scan, days
0 0–1 0 0–1 0 0–1 0.277
Skeletal muscle area, cm2 136.5 ±39.0 143.5 ±38.9 120.3 ±33.0 <0.001
Skeletal muscle index, cm2/m2 44.8 ±11.0 46.6 ±10.6 40.4 ±9.9 <0.001
Low skeletal muscle area3, n (%) 312 63.5% 163 54.5% 137 83.0% <0.001
SMD, HU 29.9 ±11.7 31.4 ±11.7 25.1 ±9.4 <0.001
IMAT, cm2 13.6 8.4–24.3 13.3 7.9–23.2 17.1 10.5–27.1 0.004
Visceral adipose tissue,
cm2 (n = 337)
96.7 49.3–170.6 95.8 50.9–178.1 108.1 54.1–177.5 0.593
Subcutaneous adipose tissue,
cm2 (n = 337)
132.7 90.2–182.4 133.7 89.8–189.2 127.7 95.7–176.2 0.440
1Survivors and non-survivors 6 months after ICU admission
2WHO categories: underweight, BMI <18.5; normal weight: BMI 18.5–24.9; overweight: BMI 25–29.9; obesity: BMI ≥30 [42]
3Defined by skeletal muscle area: <170 cm2 for males and <110 cm2 for females [9]
a, bValues in the same row not sharing the same superscript letter are significantly different in a post-hoc Bonferroni analysis
Values in bold indicate statistically significant p values
APACHE Acute Physiological, Age, and Chronic Health Evaluation, BMI, body mass index, CT computed tomography, HU Hounsfield Units, ICU intensive care unit,
IMAT intermuscular adipose tissue, IQR interquartile range, SD standard deviation, SMD skeletal muscle density
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adjusted for APACHE II score alone or the confounders
APACHE II score, BMI, and skeletal muscle area the
association between IMAT and 6-month mortality was not
significant (HR per 10 cm2, 1.092; 95% CI, 0.966–1.236;
p = 0.159).
Analyses in the subgroup with visceral and subcutaneous
adipose tissue
Additional Cox regression analyses were performed in
the subgroup of patients with available data on visceral
and subcutaneous adipose tissue (n = 337, Table 3).
Patients in this subgroup were significantly different
from patients in whom visceral and/or subcutaneous
adipose tissue could not be analysed. They were younger
(56 vs. 64 years; p < 0.001), more often male (66 vs. 55%;
p = 0.021), and had a lower BMI (24.8 vs. 25.9 kg/m2;
p = 0.026). In this subgroup, we found both SMD (HR
per 10 HU, 0.623; 95% CI 0.524–0.739; p < 0.001) and
IMAT (HR per 10 cm2, 1.245; 95% CI, 1.106–1.401;
p < 0.001) were significantly associated with 6-month
mortality. In multivariable analyses both SMD (HR
per 10 HU, 0.728; 95% CI, 0.571–0.928; p = 0.010) and
IMAT (HR per 10 cm2, 1.244; 95% CI, 1.048–1.476;
p = 0.012) remained significantly associated with 6-month
mortality, adjusted for APACHE II score, skeletal muscle
area, and visceral and subcutaneous adipose tissue.
Secondary outcome measures in survivors
Higher SMD was significantly associated with shorter
hospital-LOS after adjustment for APACHE II score,
BMI, and skeletal muscle area (Table 4). After re-
transformation we found that 10 HU higher SMD was
associated with a 14% shorter hospital-LOS. IMAT was
not associated with hospital LOS. Neither SMD nor
IMAT were significantly associated with the odds of be-
ing discharged to home, LOV, or ICU-LOS.
Discussion
This retrospective study in mechanically ventilated pa-
tients admitted to the ICU for 4 days or longer shows
that low skeletal muscle quality at ICU admission, as
assessed by skeletal muscle density on CT scans, is asso-
ciated with higher 6-month mortality independent of
muscle quantity, APACHE II score, and BMI. A lower
SMD was also associated with a longer hospital stay in
survivors. This is the first study investigating the relation
between CT-derived markers for muscle quality and out-
come in ventilated critically ill patients. Intermuscular
adipose tissue was also associated with mortality but not
independently, suggesting that SMD is a stronger marker
of muscle quality for 6-month mortality or that IMAT is
better represented by confounders than SMD.
Muscle quality and quantity
Previously we have found that low muscle quantity as
assessed by skeletal muscle area on CT scans at ICU
admission is a risk factor for hospital mortality, inde-
pendent of sex and APACHE II score [9]. These findings
were in line with a study by Moisey et al. in elderly in-
jured ICU patients, who found low skeletal muscle area
Table 2 Primary and secondary outcome measures
n % Days IQR
Six-month mortality 165 35.6%
ICU mortality 84 17.1%
Hospital mortality 132 26.9%
Length of ventilation 11 6–20
ICU length of stay 13 7–23
Hospital length of stay 35 19–59
Destination after discharge
Home 144 40.7%
Other hospital 80 22.6%
Nursing home 76 21.5%
Rehabilitation unit 45 12.7%
Other 9 2.5%
ICU intensive care unit, IQR interquartile range
Fig. 3 Kaplan-Meier plots. These graphs illustrate mortality for groups
below and above median skeletal muscle density (SMD) (29.2 Hounsfield
Units) and median intermuscular adipose tissue (IMAT) (13.6 cm2).
ICU intensive care unit
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to be associated with higher mortality and less
ventilator-free and ICU-free days [10]. In the present
study, we found that the quality of muscle appeared to
be important for survival in addition to quantity.
The APACHE II score is the best validated prognostic
ICU score for hospital mortality incorporating age, comor-
bidities, and acute illness. However, it appears that, inde-
pendently of APACHE II score, a poor health status as
reflected by low muscle quantity and quality (whether due
to inactivity, comorbidity, or high age) are important
prognostic markers. Unfortunately, the updated APACHE
III and IV scores were not available for all patients.
Of interest, IMAT was independently associated with
6-month mortality in a subgroup, but not in the entire
cohort. The patients in the subgroup were younger,
more often male, and had a lower BMI. Apparently,
visceral tissue on CT scans can more often not be ana-
lysed in older patients with high BMI, mostly because a
part of the scan is often cut-off in the windowing
process.
Causes and consequences of myosteatosis
Previous studies have shown that inactivity, as seen in
pre-existing illness and advancing age, can cause an in-
crease in myosteatosis (as seen by a decrease in SMD and
an increase in IMAT) and that these changes are associ-
ated with decreased muscle strength [24–26]. During in-
activity there is a decrease in lipoprotein lipase activity,
the rate-limiting enzyme in triglyceride metabolism, which
hydrolyses triglycerides into lipoproteins [27, 28]. Add-
itionally, during bed rest a decrease in 3-hydroxyacyl-
CoA-dehydrogenase concentration is seen, which impairs









6-month mortality HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
SMD (per 10 HU) 0.640 0.552–0.742 <0.001 0.703 0.605–0.818 <0.001 0.774 0.643–0.931 0.006 0.728 0.571–0.928 0.010
IMAT (per 10 cm2) 1.153 1.042–1.277 0.006 1.092 0.980–1.217 0.110 1.092 0.966–1.236 0.159 1.244 1.048–1.476 0.012
Model 2: adjusted for APACHE II score
Model 3: adjusted for APACHE II score, skeletal muscle area, and BMI
Model 4 (subgroup analysis): adjusted for APACHE II score, skeletal muscle area, visceral adipose tissue, and subcutaneous adipose tissue
Values in bold indicate statistically significant p values
APACHE Acute Physiological, Age, and Chronic Health Evaluation, CI confidence interval, HR hazard ratio, HU Hounsfield Units, IMAT intermuscular adipose tissue,
SMD skeletal muscle density
Table 4 Logistic and linear regression: association between skeletal muscle density or intermuscular adipose tissue and
secondary outcomes
Univariable Model 2 Model 3
OR/B 95% CI P value OR/B 95% CI P value OR/B 95% CI P value
Discharge to home
SMD (per 10 HU) 1.039 0.864 to 1.250 0.683 0.990 0.816 to 1.200 0.915 0.926 0.718 to 1.195 0.556
IMAT (per 10 cm2) 0.886 0.741 to 1.059 0.182 0.912 0.761 to 1.093 0.317 0.884 0.715 to 1.093 0.254
Length of ventilation
SMD (per 10 HU) –0.038 –0.107 to 0.032 0.292 –0.003 –0.075 to 0.069 0.936 –0.018 –0.111 to 0.075 0.705
IMAT (per 10 cm2) 0.050 –0.014 to 0.115 0.126 0.029 –0.036 to 0.094 0.384 0.026 –0.049 to 0.101 0.499
Length of ICU stay
SMD (per 10 HU) –0.051 –0.123 to 0.020 0.158 –0.020 –0.092 to 0.053 0.598 –0.032 –0.128 to 0.063 0.506
IMAT (per 10 cm2) 0.064 –0.003 to 0.130 0.059 0.043 –0.023 to 0.110 0.199 0.041 –0.036 to 0.119 0.292
Length of hospital stay
SMD (per 10 HU) –0.123 –0.192 to –0.054 0.001 –0.112 –0.184 to –0.041 0.002 –0.134 –0.228 to –0.040 0.005
IMAT (per 10 cm2) 0.075 0.010 to 0.140 0.023 0.065 –0.001 to 0.131 0.052 0.064 –0.012 to 0.141 0.100
Model 2: adjusted for APACHE II score
Model 3: adjusted for APACHE II score, skeletal muscle area, and BMI
Discharge to home results are given as OR; length of ventilation, ICU, and hospital stay are given as B values
Values in bold indicate statistically significant p values
APACHE Acute Physiological, Age, and Chronic Health Evaluation, B beta coefficient, CI confidence interval, HU Hounsfield Units, ICU intensive care unit, IMAT
intermuscular adipose tissue, OR odds ratio, SMD skeletal muscle density
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the muscle’s ability to metabolize free fatty acids to acyl-
CoA [29, 30]. Finally, denervation causes an increase in
malonyl-CoA concentrations, which in turn inhibits the
rate-limiting enzyme responsible for transporting acyl-
CoA into the mitochondria [31]. These altered metabolic
mechanisms associated with inactivity decrease the ability
of muscles to oxidise lipids and promotes a shift in muscle
fuel utilisation from lipids towards glucose, causing accu-
mulation of lipids in the muscle [26, 32]. Manini et al.
found that 4 weeks of lower limb immobilisation in
healthy adults caused an increase in IMAT and a loss in
muscle strength independent of a decrease in muscle mass
[26]. Their findings support the idea that myosteatosis is
related to decreased muscle quality.
Adipose tissue has been noted as a major endocrine
organ. To date, hundreds of adipokines, cytokines secreted
by adipose tissue, have been identified [33]. Myosteatosis is
associated with an upregulation of macrophage and T-cell
expression [34]. These inflammatory cells produce pro-
inflammatory cytokines such as tumour necrosis factor-
alpha (TNFα) and interleukin-6 (IL-6) [35] which mediate
contractile dysfunction [36, 37] and create a low-grade
inflammatory environment in which the metabolic syn-
drome, cardiovascular disease, and insulin resistance are
prone to develop [16, 17, 34].
Muscle wasting and long-term outcome
Previous studies have shown that muscle wasting as oc-
curring during critical illness has a large impact on sur-
vival, successful weaning from ventilation, and long-term
functioning [3–8, 38]. Herridge et al. found functional
disability in survivors of acute respiratory distress syn-
drome as much as 5 years after admission to the ICU [7]
and Iwashyna et al. found functional limitations up to
8 years after severe sepsis [8]. A decrease in muscle
quality as assessed by CT scans has been described in 15
patients in a small substudy of the EPaNIC trial where a
substantial decrease in skeletal muscle area and SMD,
and an increase in IMAT developing over a 7-day period
during the early stage of critical illness was found [39].
In two observational studies including 136 and 115 pa-
tients requiring at least 5 and 7 days of mechanical ven-
tilation, respectively, muscle weakness acquired during
critical illness was associated with increased ICU and
hospital mortality [3, 38]. Our study found that low
muscle quality present at the beginning of critical illness
was already associated with poor outcome, before the
devastating effects of critical illness on muscle wasting.
Strengths and limitations
Our study has strengths and limitations. This is the first
study up to now investigating the relation between muscle
quality assessed with CT scans and clinical outcomes in a
large group of critically ill ventilated patients. However,
we only included patients who had a CT scan made and
the resulting selection bias might limit the generalizability
of our findings to the overall ICU population. The
APACHE II score of the study population was higher than
the overall ICU population, all patients were ventilated,
and had an ICU length of stay of at least 4 days, indicating
that the study patients were severely ill. Low muscle
quality at admission likely has greater impact in the more
severely ill patients, because the effect of additional critical
illness-related muscle wasting is greater in this population.
Muscle quality is typically defined as muscle strength
per unit of muscle mass or cross-sectional area. However,
measuring muscle strength in ventilated critically ill pa-
tients is not feasible. Therefore, we used SMD and IMAT
as proxy markers for muscle quality [40]. To date, SMD
on CT scans has been related to myosteatosis [14, 23].
However, in recent studies in ICU patients using ultra-
sound, a relation between ultrasound echogenicity and
myonecrosis in muscle biopsies has been found [2, 41].
Changes in SMD on CT scans might therefore not only
reflect myosteatosis, but also myonecrosis. A prospective
study using CT scans and muscle biopsies will have to fur-
ther elucidate which changes in muscle are reflected by
SMD in ICU patients.
A further limitation to our study is its observational de-
sign, precluding any deduction of causality. In addition,
the complexity of critical illness may obscure residual con-
founding. Finally, the focus of our study was the predic-
tion of long-term mortality at ICU admission, e.g. whether
muscle quality at admission is a predictor of long-term
mortality independent of muscle mass and of the best vali-
dated predictive score (APACHE). Further studies are
needed to determine the risk factors for poor muscle
quality and to determine the additional impact of ICU-
acquired weakness on long-term mortality.
Conclusions
Low skeletal muscle quality at ICU admission, as assessed
by skeletal muscle density on CT scans, is associated with
higher 6-month mortality in mechanically ventilated pa-
tients, independent of muscle quantity, APACHE II score,
and BMI. Low muscle quality was also associated with
longer hospital length of stay in survivors. Therefore,
muscle quality appears to be as important for outcome as
muscle quantity. Future intervention studies, including
nutrition and early exercise, should not only focus on pre-
venting further deterioration of muscle quantity, but also
of muscle quality.
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